These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30925320)

  • 21. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue.
    Koska V; Förster M; Brouzou K; Hatami M; Arat E; Aytulun A; Albrecht P; Aktas O; Küry P; Meuth SG; Kremer D
    Front Neurol; 2021; 12():696807. PubMed ID: 34248832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis: long-term remission after a high dose of cyclophosphamide.
    de Bittencourt PR; Gomes-da-Silva MM
    Acta Neurol Scand; 2005 Mar; 111(3):195-8. PubMed ID: 15691289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of progressive multiple sclerosis with cyclophosphamide].
    Zephir H; De Seze J; Sénéchal O; Stojkovic T; Ferriby D; Deliss B; Dubus B; Verier A; Hautecoeur P; Vermersch P
    Rev Neurol (Paris); 2002 Jan; 158(1):65-9. PubMed ID: 11938324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marburg Multiple Sclerosis Variant: Complete Remission with Very Early Administration of Mitoxantrone-A Case Report.
    Capet N; Levraut M; Delourme A; Thomel-Rocchi O; Bourg V; Cabre P; Vandenbos F; Mondot L; Lebrun-Frenay C
    Neurol Ther; 2022 Mar; 11(1):507-513. PubMed ID: 34859363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Critical opinions on the treatment of multiple sclerosis with immunosuppressive agents].
    Skłodowski P
    Neurol Neurochir Pol; 1993; 27(6):877-83. PubMed ID: 8164783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unilateral Left Frontal Lobe Lesion in a Marburg's Variant of Multiple Sclerosis Patient with Impaired Swallowing and Speech: A 3-Year Clinical/Brain MRI Follow-up.
    Jovana IB; Sarlota MT; Ivan NP; Jelena DS
    Neurol India; 2022; 70(3):1226-1229. PubMed ID: 35864673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review.
    Goodin DS
    Neurology; 1991 Jul; 41(7):980-5. PubMed ID: 2067661
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
    Weiner HL; Cohen JA
    Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppressive treatment of multiple sclerosis.
    Carter JL; Rodriguez M
    Mayo Clin Proc; 1989 Jun; 64(6):664-9. PubMed ID: 2473360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balò's concentric sclerosis: still to be considered as a variant of multiple sclerosis?
    Pietroboni AM; Arighi A; De Riz MA; Ghezzi L; Calvi A; Avignone S; Scola E; Galimberti D; Triulzi F; Scarpini E
    Neurol Sci; 2015 Dec; 36(12):2277-80. PubMed ID: 26109007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside.
    Cendrowski W
    Acta Neurol Belg; 1973; 73(4):209-19. PubMed ID: 4770124
    [No Abstract]   [Full Text] [Related]  

  • 35. Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.
    Vakrakou AG; Tzanetakos D; Argyrakos T; Koutsis G; Evangelopoulos ME; Andreadou E; Anagnostouli M; Breza M; Tzartos JS; Gialafos E; Dimitrakopoulos AN; Velonakis G; Toulas P; Stefanis L; Kilidireas C
    Front Neurol; 2020; 11():536. PubMed ID: 32714265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunosuppressive therapy of multiple sclerosis using cyclophosphamide with few side effects].
    Kornhuber HH; Mauch E
    Dtsch Med Wochenschr; 1986 Nov; 111(46):1778. PubMed ID: 3780443
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.
    Dastgir J; DiMario FJ
    J Child Neurol; 2009 Apr; 24(4):431-7. PubMed ID: 19189932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractory Longitudinally Extensive Transverse Myelitis Responsive to Cyclophosphamide.
    Baxter LJ; Chen S; Couillard P; Scott JN; Doig CJ; Costello F; Girard LP; Klassen J; Burton JM
    Can J Neurol Sci; 2017 Nov; 44(6):736-739. PubMed ID: 28724464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.
    Openshaw H; Lund BT; Kashyap A; Atkinson R; Sniecinski I; Weiner LP; Forman S
    Biol Blood Marrow Transplant; 2000; 6(5A):563-75. PubMed ID: 11071262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
    Khan OA; Zvartau-Hind M; Caon C; Din MU; Cochran M; Lisak D; Tselis AC; Kamholz JA; Garbern JY; Lisak RP
    Mult Scler; 2001 Jun; 7(3):185-8. PubMed ID: 11475443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.